{"filing":{"accession_number":"0001213900-26-084260","cik":"0001877971","ticker":"POM","company_name":"POMDOCTOR Ltd","form":"6-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"ea0299159-6k_pomdoctor.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1877971/000121390026084260/ea0299159-6k_pomdoctor.htm"},"events":[{"id":23024,"run_id":20843,"accession_number":"0001213900-26-084260","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release discloses POMDOCTOR's strategic business structure and operational direction—a four-tier diversified revenue model spanning B2C healthcare services, AI-enabled chronic disease subscriptions, B2B enterprise services, and pharmaceutical real-world data services. While the disclosure includes historical revenue figures (RMB399.9M in FY2025), it is primarily a strategic announcement of the company's integrated healthcare ecosystem and technology expansion plans rather than a discrete earnings release or financial results announcement. The material nature reflects that this articulates the company's forward-looking operational strategy and business model evolution, which would affect a reasonable investor's assessment of the registrant's growth trajectory and competitive positioning.","company_name":"POMDOCTOR Ltd","ticker":"POM","filing_date":"2026-08-03","form":"6-K","submitted_at":null,"items":[{"id":23161,"accession_number":"0001213900-26-084260","item_number":"EX-99.1","item_title":"ea029915901ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release discloses POMDOCTOR's strategic business structure and operational direction—a four-tier diversified revenue model spanning B2C healthcare services, AI-enabled chronic disease subscriptions, B2B enterprise services, and pharmaceutical real-world data services. While the disclosure includes historical revenue figures (RMB399.9M in FY2025), it is primarily a strategic announcement of the company's integrated healthcare ecosystem and technology expansion plans rather than a discrete earnings release or financial results announcement. The material nature reflects that this articulates the company's forward-looking operational strategy and business model evolution, which would affect a reasonable investor's assessment of the registrant's growth trajectory and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:19:53.417990+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23161,"accession_number":"0001213900-26-084260","item_number":"EX-99.1","item_title":"ea029915901ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release discloses POMDOCTOR's strategic business structure and operational direction—a four-tier diversified revenue model spanning B2C healthcare services, AI-enabled chronic disease subscriptions, B2B enterprise services, and pharmaceutical real-world data services. While the disclosure includes historical revenue figures (RMB399.9M in FY2025), it is primarily a strategic announcement of the company's integrated healthcare ecosystem and technology expansion plans rather than a discrete earnings release or financial results announcement. The material nature reflects that this articulates the company's forward-looking operational strategy and business model evolution, which would affect a reasonable investor's assessment of the registrant's growth trajectory and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:19:53.417990+00:00","company_name":"POMDOCTOR Ltd","ticker":"POM","filing_date":"2026-08-03"}]}